(ABSI) Absci - Ratings and Ratios
AI, Antibody, Discovery, Therapeutic, Platform
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 86.2% |
| Value at Risk 5%th | 129% |
| Relative Tail Risk | -9.10% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.60 |
| Alpha | 8.04 |
| CAGR/Max DD | 0.23 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.569 |
| Beta | 2.041 |
| Beta Downside | 1.480 |
| Drawdowns 3y | |
|---|---|
| Max DD | 66.28% |
| Mean DD | 42.45% |
| Median DD | 47.08% |
Description: ABSI Absci December 29, 2025
Absci Corp (NASDAQ: ABSI) is a U.S.-based biotech that markets itself as a “data-first” generative-AI drug design platform, pairing large-language-model-style algorithms with high-throughput wet-lab automation to create novel antibody therapeutics. Its current pre-clinical pipeline includes ABS-101 (inflammatory bowel disease), ABS-201 (androgenic alopecia), ABS-301 (immuno-oncology), and ABS-501 (oncology). The firm leverages a network of R&D collaborations with entities such as PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle, and AMD.
Key quantitative touchpoints (as of the most recent filing) show a cash runway of roughly $45 million and a monthly burn rate near $3.5 million, implying ~12 months of liquidity absent additional financing. The AI-driven drug discovery sector is projected by McKinsey to grow at a CAGR of ≈ 40 % through 2030, driven by decreasing cost per candidate and faster lead identification-trends that directly benefit Absci’s value proposition. A material driver for ABSI’s valuation is the success of its AMD partnership, which provides access to high-performance GPU clusters that can cut model training time by up to 50 % versus standard cloud compute.
For a deeper quantitative view of ABSI’s risk-adjusted upside, you might explore the company’s profile on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-114.6m TTM) > 0 and > 6% of Revenue (6% = 168.9k TTM) |
| FCFTA -0.33 (>2.0%) and ΔFCFTA -3.37pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 5161 % (prev 2935 %; Δ 2227 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.33 (>3.0%) and CFO -80.7m > Net Income -114.6m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 5.89 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (143.8m) change vs 12m ago 26.54% (target <= -2.0% for YES) |
| Gross Margin -1811 % (prev -913.1%; Δ -898.1pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 1.17% (prev 1.79%; Δ -0.62pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -401.6 (EBITDA TTM -103.9m / Interest Expense TTM 289.0k) >= 6 (WARN >= 3) |
Altman Z'' -25.30
| (A) 0.59 = (Total Current Assets 175.0m - Total Current Liabilities 29.7m) / Total Assets 245.0m |
| (B) -2.43 = Retained Earnings (Balance) -595.2m / Total Assets 245.0m |
| warn (B) unusual magnitude: -2.43 — check mapping/units |
| (C) -0.48 = EBIT TTM -116.1m / Avg Total Assets 240.1m |
| (D) -17.16 = Book Value of Equity -594.7m / Total Liabilities 34.7m |
| Total Rating: -25.30 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 29.97
| 1. Piotroski 0.0pt |
| 2. FCF Yield -20.66% |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.03 |
| 5. Debt/Ebitda 0.03 |
| 6. ROIC - WACC (= -73.71)% |
| 7. RoE -60.19% |
| 8. Rev. Trend -43.48% |
| 9. EPS Trend 64.70% |
What is the price of ABSI shares?
Over the past week, the price has changed by +11.75%, over one month by +13.04%, over three months by +3.72% and over the past year by +15.73%.
Is ABSI a buy, sell or hold?
- Strong Buy: 5
- Buy: 4
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ABSI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 8.3 | 111.8% |
| Analysts Target Price | 8.3 | 111.8% |
| ValueRay Target Price | 3.8 | -3.6% |
ABSI Fundamental Data Overview January 04, 2026
P/S = 192.8388
P/B = 2.495
Beta = 2.14
Revenue TTM = 2.81m USD
EBIT TTM = -116.1m USD
EBITDA TTM = -103.9m USD
Long Term Debt = 65.0k USD (from longTermDebt, last quarter)
Short Term Debt = 3.06m USD (from shortTermDebt, last quarter)
Debt = 6.22m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -3.26m USD (from netDebt column, last quarter)
Enterprise Value = 396.6m USD (542.8m + Debt 6.22m - CCE 152.5m)
Interest Coverage Ratio = -401.6 (Ebit TTM -116.1m / Interest Expense TTM 289.0k)
FCF Yield = -20.66% (FCF TTM -81.9m / Enterprise Value 396.6m)
FCF Margin = -2911 % (FCF TTM -81.9m / Revenue TTM 2.81m)
Net Margin = -4071 % (Net Income TTM -114.6m / Revenue TTM 2.81m)
Gross Margin = -1811 % ((Revenue TTM 2.81m - Cost of Revenue TTM 53.8m) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev -3350 %)
Tobins Q-Ratio = 1.62 (Enterprise Value 396.6m / Total Assets 245.0m)
Interest Expense / Debt = 0.72% (Interest Expense 45.0k / Debt 6.22m)
Taxrate = -0.36% (negative due to tax credits) (104.0k / -28.6m)
NOPAT = -116.5m (EBIT -116.1m * (1 - -0.36%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 5.89 (Total Current Assets 175.0m / Total Current Liabilities 29.7m)
Debt / Equity = 0.03 (Debt 6.22m / totalStockholderEquity, last quarter 210.3m)
Debt / EBITDA = 0.03 (negative EBITDA) (Net Debt -3.26m / EBITDA -103.9m)
Debt / FCF = 0.04 (negative FCF - burning cash) (Net Debt -3.26m / FCF TTM -81.9m)
Total Stockholder Equity = 190.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -46.78% (Net Income -114.6m / Total Assets 245.0m)
RoE = -60.19% (Net Income TTM -114.6m / Total Stockholder Equity 190.4m)
RoCE = -60.93% (EBIT -116.1m / Capital Employed (Equity 190.4m + L.T.Debt 65.0k))
RoIC = -60.32% (negative operating profit) (NOPAT -116.5m / Invested Capital 193.1m)
WACC = 13.38% (E(542.8m)/V(549.1m) * Re(13.53%) + D(6.22m)/V(549.1m) * Rd(0.72%) * (1-Tc(-0.00)))
Discount Rate = 13.53% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 9.95%
Fair Price DCF = unknown (Cash Flow -81.9m)
EPS Correlation: 64.70 | EPS CAGR: 37.39% | SUE: 4.0 | # QB: 1
Revenue Correlation: -43.48 | Revenue CAGR: -30.15% | SUE: -1.49 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.17 | Chg30d=-0.008 | Revisions Net=+1 | Analysts=4
EPS next Year (2026-12-31): EPS=-0.67 | Chg30d=-0.001 | Revisions Net=+4 | Growth EPS=+16.1% | Growth Revenue=+382.2%
Additional Sources for ABSI Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle